MUMBAI, India, July 25 -- Intellectual Property India has published a patent application (202421003897 A) filed by Macs-Agharkar Research Institute; and School Of Biosciences, Mahatma Gandhi University, Pune, Maharashtra, on Jan. 19, 2024, for 'endophytic penicillium setosum svws1 derived anticancer compound for breast cancer therapeutics.'
Inventor(s) include Sherin Varghese; Jisha M. S.; Virendra Gajbhiye; and Rajesh Kumar K. C.
The application for the patent was published on July 25, under issue no. 30/2025.
According to the abstract released by the Intellectual Property India: "The present invention explores a promising anticancer agent, 4-hydroxy-4,6-dihydrofuro[3,2-c]pyran-2-one (HDP), synthesized by fungal endophyte Penicillium setosum SVWS1, isolated from the roots of Withania somnifera. This compound shows potent selective cytotoxicity against MDA MB-468 and MCF-7 breast cancer cell lines while maintaining safety for healthy cells, particularly L929 Fibroblast cells. It can effectively interact with breast cancer's five selected target receptors (ERa, PR, EGFR, mTOR and HER2). The compound's pharmacokinetic profiling indicates a favorable therapeutic profile, making it a promising candidate for anticancer drug development. The purification process involves preparative HPTLC and subsequent HPLC for purity assessment. Its structure is confirmed by 1H NMR spectroscopy and MS/MS data. Mechanistically, the anticancer agent induces apoptosis in MCF-7 cells, evidenced by the activation of caspase 3 and 7. In conclusion, the invention highlights HDP as a distinctive and prospective anticancer compound with unique ability to selectively target breast cancer cells."
Disclaimer: Curated by HT Syndication.
